2 Reasons Why Eli Lilly’s Mounjaro Might Beat Novo Nordisk’s Ozempic, and 2 Reasons Why It Might Not
Eli Lilly’s drug looks better on paper, but Ozempic was on the market first.
Mindfully Curated
Eli Lilly’s drug looks better on paper, but Ozempic was on the market first.
The cloud market is booming, and these companies could profit significantly from its development.
AMD is often compared to Nvidia, but the two are quite different.
An early filing will generally leave you with a reduced monthly benefit for life, but you may be able to get out of that.
Sharply higher interest rates are hammering solar stocks in several ways.
Nvidia’s return on invested capital stands head and shoulders above even its top peers.
Riding out the hills and valleys of Shiba Inu’s price moves requires an abundance of faith and a strong stomach.
StoneCo just announced a new repurchase authorization. Here’s why that’s great news for investors.
AT&T’s dividend looks safe, but there are other factors investors should consider.
The smaller e-commerce platform has a unique value proposition.
For investors with time on their side, combining the power of dollar-cost averaging and Bitcoin could be a recipe for success.
Microsoft is the AI stock to watch for the next decade.
This broken IPO is coming back with a vengeance.
Social Security may not be as reliable as it once was.
Even after its recovery began, AMD offered considerable potential for gains.
Federal student loan borrowers are required to make payments in October for the first time since early 2020.
This company has grabbed plenty of headlines this year, and they haven’t all been good.
This is a great move for the company and investors. For Prime members? Not so much.
Moderna, Pfizer, and Novavax all are working on combined vaccine candidates.
Utilities have gotten rocked by higher interest rates.